Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Kroger Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Kroger Co trades at $58.69 (market cap $35.99B). The key difference: Kroger Co is far larger — about 4.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Kroger Co pays a 2.45% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | KR | |
|---|---|---|
Market Cap | $8.04B | $35.99B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $75.60 |
52-Week Low | $241.71 | $55.53 |
Enterprise Value | $7.85B | $56.08B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Kroger (KR) trades at $59.31, down 2.03% today, with technical indicators showing bearish momentum. The company maintains stable revenue around $147B with improving net margins (1.81% in 2025) and recently announced a $1.65B acquisition of Giant Eagle to expand Midwest presence. Strong cash flow generation ($2.08B net in 2025) supports dividend payments and strategic investments.
Kroger presents a mixed outlook with attractive valuation metrics (P/S 0.26) and analyst consensus target of $68.63 offering 16% upside potential. However, competitive pressures, recent earnings miss, and bearish technical signals warrant caution. The Giant Eagle acquisition provides growth opportunity but integration risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
